167 related articles for article (PubMed ID: 22989076)
1. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
Onishi M; Ichikawa T; Kurozumi K; Fujii K; Yoshida K; Inoue S; Michiue H; Chiocca EA; Kaur B; Date I
Neuropathology; 2013 Apr; 33(2):162-74. PubMed ID: 22989076
[TBL] [Abstract][Full Text] [Related]
2. Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas.
Inoue S; Ichikawa T; Kurozumi K; Maruo T; Onishi M; Yoshida K; Fujii K; Kambara H; Chiocca EA; Date I
World Neurosurg; 2012 Dec; 78(6):670-82. PubMed ID: 22120277
[TBL] [Abstract][Full Text] [Related]
3. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
[TBL] [Abstract][Full Text] [Related]
4. Proteomics-based analysis of invasion-related proteins in malignant gliomas.
Maruo T; Ichikawa T; Kanzaki H; Inoue S; Kurozumi K; Onishi M; Yoshida K; Kambara H; Ouchida M; Shimizu K; Tamaru S; Chiocca EA; Date I
Neuropathology; 2013 Jun; 33(3):264-75. PubMed ID: 23116197
[TBL] [Abstract][Full Text] [Related]
5. Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma.
Onishi M; Ichikawa T; Kurozumi K; Inoue S; Maruo T; Otani Y; Fujii K; Ishida J; Shimazu Y; Yoshida K; Michiue H; Antonio Chiocca E; Date I
Brain Tumor Pathol; 2015 Jul; 32(3):184-94. PubMed ID: 25697644
[TBL] [Abstract][Full Text] [Related]
6. Cilengitide treatment for malignant glioma: current status and future direction.
Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
[TBL] [Abstract][Full Text] [Related]
8. Cilengitide induces autophagy-mediated cell death in glioma cells.
Lomonaco SL; Finniss S; Xiang C; Lee HK; Jiang W; Lemke N; Rempel SA; Mikkelsen T; Brodie C
Neuro Oncol; 2011 Aug; 13(8):857-65. PubMed ID: 21788343
[TBL] [Abstract][Full Text] [Related]
9. Cilengitide inhibits metastatic bone colonization in a nude rat model.
Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
[TBL] [Abstract][Full Text] [Related]
10. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of cilengitide with belotecan against experimental glioblastoma.
Kim YH; Lee JK; Kim B; DeWitt JP; Lee JE; Han JH; Kim SK; Oh CW; Kim CY
Int J Cancer; 2013 Aug; 133(3):749-56. PubMed ID: 23354807
[TBL] [Abstract][Full Text] [Related]
12. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
13. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
[TBL] [Abstract][Full Text] [Related]
14. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a canine glioma cell line as related to established experimental brain tumor models.
Rainov NG; Koch S; Sena-Esteves M; Berens ME
J Neuropathol Exp Neurol; 2000 Jul; 59(7):607-13. PubMed ID: 10901232
[TBL] [Abstract][Full Text] [Related]
16. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
17. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.
Bäuerle T; Komljenovic D; Merz M; Berger MR; Goodman SL; Semmler W
Int J Cancer; 2011 May; 128(10):2453-62. PubMed ID: 20648558
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
MacDonald TJ; Vezina G; Stewart CF; Turner D; Pierson CR; Chen L; Pollack IF; Gajjar A; Kieran MW
Neuro Oncol; 2013 Oct; 15(10):1438-44. PubMed ID: 24014381
[TBL] [Abstract][Full Text] [Related]
20. Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.
Nagaraja TN; Aryal MP; Brown SL; Bagher-Ebadian H; Mikkelsen T; Yang JJ; Panda S; Keenan KA; Cabral G; Ewing JR
PLoS One; 2013; 8(12):e84493. PubMed ID: 24376814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
